Literature DB >> 8948372

Idiopathic genital ulcers in women infected with human immunodeficiency virus.

J Anderson1, R A Clark, D H Watts, M Till, C Arrastia, P Schuman, S E Cohn, M Young, L Bessen, R Greenblatt, M Vogler, S Swindells, P Boyer.   

Abstract

A national survey of investigators caring for human immunodeficiency virus (HIV)-infected women was undertaken to describe the clinical presentation of idiopathic genital ulcer disease. Patients with negative syphilis and herpes simplex testing and/or negative genital ulcer biopsy were included in this study. Study participants (n = 29) were generally severely immunocompromised (median CD4 cell count was 50/mm3, and 68% had an acquired immunodeficiency syndrome [AIDS]-defining opportunistic process). Thirty-seven percent had coexistent oral ulcers and 19% had their genital ulcer progress to fistula formation (four rectovaginal and one vaginal-perineal). There was generally a favorable response to topical, systemic, and intralesional steroid treatment. This study suggests that idiopathic or probable aphthous genital ulcers in women have similar clinical characteristics to aphthous oroesophageal ulcers. Although infrequent, these genital ulcers can cause severe morbidity. Further research is warranted to better define the pathophysiology and optimal management.

Entities:  

Mesh:

Year:  1996        PMID: 8948372     DOI: 10.1097/00042560-199612010-00007

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  2 in total

1.  Possible reasons for an increase in the proportion of genital ulcers due to herpes simplex virus from a cohort of female bar workers in Tanzania.

Authors:  Gabriele Riedner; Jim Todd; Mary Rusizoka; Donan Mmbando; Leonard Maboko; Eligius Lyamuya; Oliver Hoffmann; I MacLean; Heiner Grosskurth; Richard Hayes
Journal:  Sex Transm Infect       Date:  2006-09-13       Impact factor: 3.519

2.  Nontrichomonal Purulent Vaginitis: Clinical Approach.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.663

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.